Pediatric Drug Therapy: Generic Drugs and Drug Pricing
This module focuses on how generic drugs are approved and what drives drug pricing.
OBJECTIVES FOR LEARNING OUTCOMES
At the conclusion of this activity, participants will be better able to:
Describe how a drug is licensed, what the difference is between an NDA and an ANDA, and the intellectual property considerations that underlie the distinction.
Enumerate the key players (PBMs, pharamceutical companies, regulators, etc.) that affect drug pricing.
Propose regulatory frameworks that would make prescription medications more accessible.
Presentation & Handout
Dan Leifer, MD Resident Physician in Dermatology and Board-Certified Pediatrician, Division of Dermatology, UW